IDWeek data reinforces AstraZeneca’s commitment to advance science in vaccines and immune therapies
Additional analyses from TACKLE Phase III treatment trial further demonstrate Evusheld’s potential to reduce COVID-19 severity and mortality.Analysis of long-acting antibody Beyfortus across respiratory syncytial virus (RSV) season further underscores the potential of the investigational treatment to be the first and only single-dose preventative option for all infants.AstraZeneca will showcase new data across its Vaccines and Immune Therapies portfolio at the 11[th] annual IDWeek conference, 19 – 23 October 2022, reinforcing its commitment to deliver long-lasting immunity for millions of